Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin AmyloidosisDavid Adams, Ole B. Suhr, Alejandra González‐Duarte et al.|New England Journal of Medicine|2018Cited by 2.9k
Safety and Efficacy of RNAi Therapy for Transthyretin AmyloidosisTeresa Coelho, Ole B. Suhr, David Adams et al.|New England Journal of Medicine|2013Cited by 961
Impairment of Mycobacterial Immunity in Human Interleukin-12 Receptor DeficiencyFrédéric Altare, Jean‐Laurent Casanova, Rainer Döffinger et al.|Science|1998Cited by 840
POS0479 STAT3 DEGRADERS PROTECT FROM IMMUNOFIBROTIC CHANGES IN PRECLINICAL MODELSP. Blyszczuk, Oliver Distler, Elena Pachera et al.|Annals of the Rheumatic Diseases|2022Cited by 0